{"id":"bevacizumab-bev","safety":{"commonSideEffects":[{"rate":"20–40%","effect":"Hypertension"},{"rate":"20–30%","effect":"Proteinuria"},{"rate":"15–25%","effect":"Hemorrhage (all grades)"},{"rate":"10–15%","effect":"Thromboembolism"},{"rate":"0.5–2%","effect":"Gastrointestinal perforation"},{"rate":"5–10%","effect":"Wound healing complications"},{"rate":"15–20%","effect":"Fatigue"},{"rate":"10–15%","effect":"Diarrhea"},{"rate":"2–5%","effect":"Congestive heart failure"}]},"_chembl":null,"_dailymed":{"setId":"6b4040a2-a5c5-4ff0-ab45-935d7e49cf78","title":"ALYMSYS (BEVACIZUMAB-MALY) INJECTION, SOLUTION [AMNEAL PHARMACEUTICALS LLC]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Bevacizumab binds to circulating VEGF, a key signaling protein that promotes angiogenesis (new blood vessel growth). By neutralizing VEGF, the drug inhibits the formation of new blood vessels that tumors require to grow and metastasize. This anti-angiogenic mechanism reduces tumor perfusion and can slow or halt cancer progression.","oneSentence":"Bevacizumab is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF), preventing tumor blood vessel formation and starving tumors of oxygen and nutrients.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:24:47.531Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic colorectal cancer (in combination with chemotherapy)"},{"name":"Metastatic non-small cell lung cancer (in combination with chemotherapy)"},{"name":"Metastatic breast cancer (in combination with chemotherapy)"},{"name":"Glioblastoma (recurrent)"},{"name":"Metastatic renal cell carcinoma (in combination with interferon-alpha)"},{"name":"Cervical cancer (in combination with chemotherapy)"}]},"trialDetails":[{"nctId":"NCT07481786","phase":"PHASE3","title":"Bevacizumab Plus FSRT Versus Hippocampus-Avoidant WBRT in Lung Adenocarcinoma With Extensive Brain Metastases","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-03-15","conditions":"Lung Adenocarcinoma, Brain Metastases, Radiotherapy, Intensity-Modulated","enrollment":220},{"nctId":"NCT07472153","phase":"PHASE2, PHASE3","title":"PD-1 (Programmed Death-1) Versus PD-L1 (Programmed Death-ligand 1) Immune Check Point Inhibitors Combined With Chemotherapy, With or Without Bevacizumab, In Patients With Metastatic, Persistent Or Recurrent Cervical Cancer","status":"RECRUITING","sponsor":"N.N. Alexandrov National Cancer Centre","startDate":"2025-07-01","conditions":"Metastatic Cervical Cancer, Persistent Cervical Cancer, Recurrent Cervical Cancer","enrollment":120},{"nctId":"NCT07472140","phase":"PHASE2, PHASE3","title":"PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer","status":"RECRUITING","sponsor":"N.N. Alexandrov National Cancer Centre","startDate":"2025-07-01","conditions":"Ovarian Cancer, Fallopian Tube Cancers, Primary Peritoneal Cancer","enrollment":120},{"nctId":"NCT06823375","phase":"PHASE2","title":"SBRT With Immunotherapy and Atezo-Bev in HCC With Major Portal Vein Thrombosis","status":"RECRUITING","sponsor":"Chinese University of Hong Kong","startDate":"2025-07-10","conditions":"HCC","enrollment":40},{"nctId":"NCT06137170","phase":"","title":"A Real-World Study to Learn More About the Order of Different Treatments and Their Effects in People With Metastatic Colorectal Cancer Receiving Their Third and Fourth Line of Treatment","status":"COMPLETED","sponsor":"Bayer","startDate":"2024-03-01","conditions":"Metastatic Colorectal Cancer","enrollment":121},{"nctId":"NCT05739981","phase":"PHASE1, PHASE2","title":"Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer","status":"RECRUITING","sponsor":"Imunon","startDate":"2023-02-10","conditions":"Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer","enrollment":30},{"nctId":"NCT03942328","phase":"PHASE1, PHASE2","title":"Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2019-09-19","conditions":"Stage III Hepatocellular Carcinoma AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8","enrollment":85},{"nctId":"NCT05488522","phase":"PHASE1","title":"SBRT With Atezo/Bev for HCC","status":"RECRUITING","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2022-09-01","conditions":"Hepatocellular Carcinoma","enrollment":18},{"nctId":"NCT07365930","phase":"","title":"NIS on the Benefits of TIPS in Patients With HCC Receiving Atezo+Bev in 1st-Line Therapy","status":"RECRUITING","sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","startDate":"2025-12-17","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":350},{"nctId":"NCT07383285","phase":"PHASE2","title":"CAPOX and Bevacizumab With or Without Primary Tumor Radiotherapy and Iparomlimab and Tuvonralimab as First-line Treatment for RAS-Mutant/MSS Metastatic Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2026-02-01","conditions":"Rectal Neoplasms Malignant","enrollment":106},{"nctId":"NCT04712643","phase":"PHASE3","title":"A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-03-12","conditions":"Hepatocellular Carcinoma","enrollment":342},{"nctId":"NCT06739252","phase":"PHASE2","title":"Perioperative Treatment of High-risk Resectable CCA With HAIC Plus A+T: Neobrave CCA","status":"TERMINATED","sponsor":"Peking University","startDate":"2024-12-31","conditions":"Intrahepatic Cholangiocarcinoma (Icc), Perihilar Cholangiocarcinoma","enrollment":1},{"nctId":"NCT07355764","phase":"PHASE2","title":"MA-CRC-II-016 SHR-1811","status":"NOT_YET_RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2025-12-30","conditions":"mCRC, HER2, Targeted Therapy","enrollment":80},{"nctId":"NCT07347444","phase":"PHASE2","title":"Iparomlimab and Tuvoraleimab Injection in Combination With Bevacizumab, Albumin-bound Paclitaxel, and Carboplatin as First- or Second-line Treatment for Patients With Advanced Acral and Mucosal Melanoma","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2026-02","conditions":"Acral Melanoma, Mucosal Melanoma","enrollment":48},{"nctId":"NCT04649489","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Safety of Hepatic Resection for Liver Cancer With PVTT, HVTT or IVCTT After Initial Ate/Bev","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jia Fan","startDate":"2021-04-19","conditions":"Venous Thrombosis","enrollment":501},{"nctId":"NCT07337551","phase":"PHASE2","title":"Gossypol Acetate + FOLFIRI + Bev in mCRC With TP53-Mutant and LRPPRC Positive","status":"NOT_YET_RECRUITING","sponsor":"Guiying Wang","startDate":"2026-02-01","conditions":"Patients With Metastatic Colorectal Cancer Who Were TP53-mutant and LRPPRC-positive and Had Previously Failed Prior First-line Treatment","enrollment":20},{"nctId":"NCT06106308","phase":"PHASE2","title":"Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cardiff Oncology","startDate":"2024-02-27","conditions":"Metastatic Colorectal Cancer, CRC, KRAS/NRAS Mutation","enrollment":113},{"nctId":"NCT06478693","phase":"PHASE1","title":"A Study of MT-303 in Adults With Advanced or Metastatic GPC3-Expressing Cancers, Including HCC","status":"RECRUITING","sponsor":"Myeloid Therapeutics","startDate":"2024-07-01","conditions":"Hepatocellular Carcinoma","enrollment":70},{"nctId":"NCT05908786","phase":"PHASE1, PHASE2","title":"A Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2023-12-05","conditions":"Carcinoma, Hepatocellular","enrollment":62},{"nctId":"NCT07274787","phase":"NA","title":"Safety And Effectiveness Of NaviFUS System With Bevacizumab In Recurrent Glioblastoma","status":"NOT_YET_RECRUITING","sponsor":"University of Cincinnati","startDate":"2026-01-01","conditions":"GBM","enrollment":10},{"nctId":"NCT06733038","phase":"PHASE3","title":"FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR and IS IC-High Metastatic Colorectal Cancer Patients.","status":"RECRUITING","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2024-11-15","conditions":"Colorectal Cancer","enrollment":238},{"nctId":"NCT07059845","phase":"PHASE2","title":"A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer","status":"RECRUITING","sponsor":"AbbVie","startDate":"2025-11-13","conditions":"Ovarian Cancer","enrollment":320},{"nctId":"NCT07241403","phase":"","title":"Chronic Inflammation, Plasma Proteins Signature, Survival Outcomes and Clinical Response, in Patients Receiving Bevacizumab Combined With Oxaliplatin-based Chemotherapy (Bev/OX) or Bevacizumab Combined With Irinotecan-based Chemotherapy (Bev/IRI)","status":"COMPLETED","sponsor":"Second Affiliated Hospital of Nanchang University","startDate":"2018-01-01","conditions":"Colorectal Cancer, Resistance, Bevacizimab","enrollment":698},{"nctId":"NCT05839951","phase":"","title":"An Observational Study Called STAR-T to Learn More About the Sequential Treatment With Regorafenib and TAS-102 in Adults With Metastatic Colorectal Cancer Under Real World Conditions","status":"COMPLETED","sponsor":"Bayer","startDate":"2023-04-24","conditions":"Metastatic Colorectal Cancer (mCRC)","enrollment":818},{"nctId":"NCT05053750","phase":"EARLY_PHASE1","title":"TAME: A Pilot Study of Weekly Paclitaxel, Bevacizumab, and Tumor Associated Macrophage Targeted Therapy (Zoledronic Acid) in Women With Recurrent, Platinum-resistant, Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-12-14","conditions":"Epithelial Ovarian, Fallopian Tube, Primary Peritoneal Cancer","enrollment":14},{"nctId":"NCT07204327","phase":"","title":"Atezolizumab Plus Bevacizumab Combined With Locoregional Therapies in Unresectable Hepatocellular Carcinoma (ISMIO-001)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Zhongda Hospital","startDate":"2020-10-28","conditions":"Unresectable Hepatocellular Carcinoma","enrollment":1136},{"nctId":"NCT07198165","phase":"PHASE2","title":"SCRT Followed by CAPOX + Bev ± PD-1 Inhibitor for TNT in LARC","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2025-09-05","conditions":"Rectal Cancer, Rectal Adenocarcinoma, Rectal Cancer, Radiotherapy","enrollment":104},{"nctId":"NCT05678257","phase":"PHASE2","title":"A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer","status":"TERMINATED","sponsor":"NuCana plc","startDate":"2023-04-18","conditions":"Colorectal Cancer, Colorectal Neoplasms, Colorectal Adenocarcinoma","enrollment":180},{"nctId":"NCT06313970","phase":"PHASE2","title":"First-line Regimen With QL1706 Plus Chemo ± Bev in PDAC Patients","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-06-20","conditions":"Pancreatic Cancer","enrollment":58},{"nctId":"NCT07150208","phase":"PHASE2","title":"T-DXd With or Without Bevacizumab for HER2-low Breast Cancer With Brain Metastasis","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-09","conditions":"Breast Cancer With Brain Metastasis, HER2-low Expressing Breast Cancer","enrollment":140},{"nctId":"NCT06819566","phase":"PHASE2","title":"Prophylactic Endoscopic Variceal Ligation in Patients With High-risk Esophageal Varices Receiving Atezo/Bev for HCC","status":"RECRUITING","sponsor":"Asan Medical Center","startDate":"2025-05-28","conditions":"Hepatocellular Carcinoma, Esophageal Varix, Bleeding Esophageal Varices","enrollment":44},{"nctId":"NCT07047560","phase":"PHASE2","title":"Liposomal Irinotecan (II) Fractionated Dosing Combined With 5-FU/LV (FOLFIRInali-3) and Bevacizumab in Second-line Treatment of Advanced Colorectal Cancer: A Single-arm, Phase II Clinical Study","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2024-09-01","conditions":"Colorectal Cancer (CRC)","enrollment":46},{"nctId":"NCT05330429","phase":"PHASE2","title":"Study of Magrolimab Given Together With FOLFIRI/Bevacizumab (BEV) in Participants With Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC)","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2022-07-08","conditions":"Metastatic Colorectal Cancer","enrollment":77},{"nctId":"NCT07018947","phase":"PHASE2","title":"Study to Evaluate the Efficacy and Safety of Atezolizumab and Bevacizumab as Neoadjuvant Plus Adjuvant Treatment in HCC","status":"NOT_YET_RECRUITING","sponsor":"Fundacion Clinic per a la Recerca Biomédica","startDate":"2025-11","conditions":"Resectable Hepatocellular Carcinoma","enrollment":90},{"nctId":"NCT05763277","phase":"","title":"Ate-Bev Early Response Prediction Model in Advanced HCC","status":"RECRUITING","sponsor":"Seoul National University Hospital","startDate":"2022-07-22","conditions":"Hepatocellular Carcinoma, Atezolizumab-bevacizumab, Response Evaluation","enrollment":170},{"nctId":"NCT06903663","phase":"","title":"The Epidemiology of Patients Treated With ATZ+BEV in Real Life Setting","status":"NOT_YET_RECRUITING","sponsor":"Institutul Regional de Gastroenterologie & Hepatologie Prof. dr. Octavian Fodor","startDate":"2025-04","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":100},{"nctId":"NCT06503250","phase":"","title":"A Study of Participants With Initially Unresectable Hepatocellular Carcinoma That is Treated With Atezolizumab and Bevacizumab Plus Transarterial Chemoembolization","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2024-07-19","conditions":"Unresectable Hepatocellular Carcinoma","enrollment":113},{"nctId":"NCT04997382","phase":"PHASE2","title":"Chemotherapy Combined with ICIs in First-line Alectinib Failed Patients with ALK-rearranged NSCLC","status":"COMPLETED","sponsor":"Hunan Province Tumor Hospital","startDate":"2021-08-17","conditions":"Non-small Cell Lung Cancer","enrollment":112},{"nctId":"NCT05984511","phase":"NA","title":"TACE Plus Atezolizumab/Bevacizumab and I-125 Seeds Brachytherapy for HCC With Branch PVTT","status":"RECRUITING","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2023-08-30","conditions":"Hepatocellular Carcinoma, Hepatic Portal Vein Tumor Invasion, Tumor Thrombus","enrollment":234},{"nctId":"NCT06788171","phase":"PHASE2","title":"PULSAR Combined With PD-1 Ab and Chemotherapy Plus Bev. for CRLM","status":"NOT_YET_RECRUITING","sponsor":"Fujian Cancer Hospital","startDate":"2025-03-01","conditions":"Colorectal Cancer Liver Metastasis","enrollment":35},{"nctId":"NCT06737913","phase":"PHASE2","title":"HAI or IV of Adebrelimab, Combined with Bevacizumab and HAI of FOLFOX for Advanced Unresectable Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-12","conditions":"Advanced Hepatocellular Carcinoma (HCC)","enrollment":78},{"nctId":"NCT05969899","phase":"PHASE2","title":"Liposomal Irinotecan Based FOLFIRI With Bevacizumab in First-line Treatment of Advanced Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fudan University","startDate":"2023-07-10","conditions":"Colorectal Cancer","enrollment":50},{"nctId":"NCT06496971","phase":"PHASE3","title":"A Prospective Pivotal Study to Evaluate the Efficacy and Safety of Avastin® Bevacizumab (BEV) With or Without Microbubble-mediated Focused Ultrasound (FUS-MB) Using NaviFUS System in Recurrent Glioblastoma Multiforme Patients","status":"RECRUITING","sponsor":"NaviFUS Corporation","startDate":"2024-11-08","conditions":"Glioblastoma Multiforme, Glioblastoma, Glioblastoma Multiforme, Adult","enrollment":32},{"nctId":"NCT06540261","phase":"PHASE1","title":"The Study of ONO-7913, ONO-4538 and the Standard of Care as First-line Treatment in Patients Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2021-09-23","conditions":"Unresectable Colorectal Cancer","enrollment":65},{"nctId":"NCT06006286","phase":"PHASE1, PHASE2","title":"A Study Evaluating Atezolizumab and Bevacizumab Plus ADI-PEG 20 in Patients With Locally Advanced / Metastatic Hepatocellular Carcinoma","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2023-08-08","conditions":"Metastatic Hepatocellular Carcinoma","enrollment":""},{"nctId":"NCT04677504","phase":"PHASE2","title":"A Study of Atezolizumab With or Without Bevacizumab in Combination With Cisplatin Plus Gemcitabine in Patients With Untreated, Advanced Biliary Tract Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2021-02-23","conditions":"Biliary Tract Cancer","enrollment":162},{"nctId":"NCT04224636","phase":"PHASE2","title":"Atezolizumab/Bevacizumab Followed by On-demand TACE or Initial Synchronous Treatment With TACE and Atezolizumab/Bevacizumab","status":"RECRUITING","sponsor":"Ludwig-Maximilians - University of Munich","startDate":"2020-06-10","conditions":"Hepatocellular Carcinoma Non-resectable","enrollment":106},{"nctId":"NCT06397222","phase":"PHASE2","title":"Sintilimab Plus Bevacizumab and SIRT for Intermediate-advanced HCC","status":"RECRUITING","sponsor":"Second Affiliated Hospital of Guangzhou Medical University","startDate":"2024-05-01","conditions":"Hepatocellular Carcinoma Non-resectable","enrollment":23},{"nctId":"NCT06206096","phase":"PHASE2","title":"PD-1 Antibody Plus Bevacizumab and CAPOX as First-line Treatment for RAS-mut MSS mCRC","status":"RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2021-05-26","conditions":"Colorectal Cancer, RAS Mutation, Colorectal Neoplasms","enrollment":40},{"nctId":"NCT06371586","phase":"PHASE2","title":"Neo-Sequence 2：NCT Plus Anti-angiogenesis Therapy and Immunotherapy for LADGC","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2024-03-01","conditions":"Gastric Cancer, Diffuse Type Carcinoma","enrollment":67},{"nctId":"NCT06329570","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multiforme (rGBM)","status":"NOT_YET_RECRUITING","sponsor":"NaviFUS Corporation","startDate":"2024-07-01","conditions":"Glioblastoma Multiforme, Glioblastoma, Glioma","enrollment":10},{"nctId":"NCT02399410","phase":"PHASE2","title":"Perioperative Chemotherapy With Bevacizumab for Colorectal Carcinomatosis","status":"COMPLETED","sponsor":"University Hospital, Ghent","startDate":"2015-11-04","conditions":"Colorectal Neoplasms","enrollment":60},{"nctId":"NCT03439462","phase":"PHASE1, PHASE2","title":"Nab-Sirolimus in Combination With FOLFOX & BEV as 1st Line Therapy in Patients With Advanced or Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Aadi Bioscience, Inc.","startDate":"2018-07-01","conditions":"Colorectal Cancer Metastatic","enrollment":60},{"nctId":"NCT03485027","phase":"PHASE2","title":"Rechallenge of Prior Regimen in Third or Later-line Chemotherapy in Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Fudan University","startDate":"2018-01-24","conditions":"Metastatic Colorectal Cancer, Chemotherapy Effect","enrollment":43},{"nctId":"NCT03425292","phase":"PHASE1","title":"A Longitudinal Assessment of Tumor Evolution in Patients With Brain Cancer","status":"COMPLETED","sponsor":"Saint John's Cancer Institute","startDate":"2018-03-01","conditions":"Newly Diagnosed High Grade Glioma","enrollment":49},{"nctId":"NCT03721653","phase":"PHASE2","title":"FOLFOXIRI + Bev + Atezo vs FOLFOXIRI + Bev as First-line Treatment of Unresectable Metastatic Colorectal Cancer Patients","status":"COMPLETED","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2018-11-30","conditions":"Metastatic Colorectal Cancer","enrollment":218},{"nctId":"NCT06031376","phase":"","title":"Fruquintinib With PD-1 Inhibitors Versus TAS-102 With Bevacizumab in Late-Line mCRC","status":"COMPLETED","sponsor":"Hunan Cancer Hospital","startDate":"2019-07-01","conditions":"Metastatic Colorectal Adenocarcinoma","enrollment":106},{"nctId":"NCT04446416","phase":"NA","title":"Efficacy and Safety of NaviFUS System add-on Bevacizumab (BEV) in Recurrent GBM Patients","status":"COMPLETED","sponsor":"NaviFUS Corporation","startDate":"2020-07-21","conditions":"Glioblastoma Multiforme, Glioblastoma, Glioma","enrollment":6},{"nctId":"NCT05985798","phase":"PHASE3","title":"Sintilimab+Bevacizumab+TACE vs. Lenvatinib+TACE for Advanced HCC","status":"RECRUITING","sponsor":"Second Affiliated Hospital of Guangzhou Medical University","startDate":"2023-08-01","conditions":"Hepatocellular Carcinoma Non-resectable","enrollment":258},{"nctId":"NCT05970302","phase":"PHASE2","title":"XELOX +Bev +Tislelizumab for First-line Treatment of MSS/pMMR RAS-mutated mCRC","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2023-07-07","conditions":"Tislelizumab, Bevacizumab, Oxaliplatin","enrollment":52},{"nctId":"NCT05718466","phase":"PHASE3","title":"Stereotactic Radiology Versus Chemotherapy for Recurrent/Progressive Glioblastoma After Second-Line Chemotherapy","status":"COMPLETED","sponsor":"Henry Ford Health System","startDate":"2010-11","conditions":"Recurrent or Progressive Glioblastoma","enrollment":35},{"nctId":"NCT00098787","phase":"PHASE2","title":"Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"2005-09-08","conditions":"Colorectal Cancer","enrollment":247},{"nctId":"NCT04217954","phase":"PHASE2","title":"HAIC With Oxaliplatin, 5-FU and Bevacizumab Plus Intravenous Toripalimab for Advanced BTC","status":"COMPLETED","sponsor":"Peking University","startDate":"2020-07-28","conditions":"Advanced Biliary Tract Cancer","enrollment":32},{"nctId":"NCT03623347","phase":"","title":"Upfront Bevacizumab/témozolomide for Gliomastomas With Neurological Impairment","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire, Amiens","startDate":"2011-01-01","conditions":"Chemoradiotherapy","enrollment":70},{"nctId":"NCT05797467","phase":"PHASE3","title":"Adjuvant Chemotherapy Combined With Targeted Therapy or Not in the T3-4N2 Colorectal Cancer Patients","status":"RECRUITING","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2023-04-01","conditions":"Colorectal Cancer, Chemotherapy Effect","enrollment":366},{"nctId":"NCT05869097","phase":"","title":"Trifluridine/Tipiracil Plus Bevacizumab Versus Trifluridine/Tipiracil Monotherapy in Refractory Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Hunan Cancer Hospital","startDate":"2020-11-01","conditions":"Metastatic Colorectal Adenocarcinoma","enrollment":90},{"nctId":"NCT05821361","phase":"PHASE2","title":"HAIC Combined With Cadonilimab and Bevacizumab as First-line Therapy in Unresectable Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2023-08-01","conditions":"Unrescetable Hepatocellular Carcinoma","enrollment":30},{"nctId":"NCT05768503","phase":"PHASE3","title":"Comparing Chidamide+Sintilimab+Bev With Standard Second-line FOLFIRI+Bev in Advanced MSS/pMMR mCRC","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-03-01","conditions":"Metastatic Microsatellite-stable Colorectal Cancer","enrollment":176},{"nctId":"NCT02761070","phase":"PHASE3","title":"Bevacizumab Alone Versus Dose-dense Temozolomide Followed by Bevacizumab for Recurrent Glioblastoma, Phase III","status":"UNKNOWN","sponsor":"Kyorin University","startDate":"2016-07-11","conditions":"Glioblastoma, Recurrence, Progression","enrollment":146},{"nctId":"NCT02343549","phase":"PHASE2","title":"A Phase II Study of Optune (NovoTTF) in Combination With Bevacizumab (BEV) and Temozolomide (TMZ) in Patients With Newly Diagnosed Unresectable Glioblastoma (GBM)","status":"TERMINATED","sponsor":"Wake Forest University Health Sciences","startDate":"2015-01","conditions":"Cancer of Brain and Nervous System","enrollment":13},{"nctId":"NCT05540951","phase":"PHASE3","title":"VIC Regimen Versus Bevacizumab Plus Chemotherapy as First-Line Treatment for BRAF V600E-Mutated Advanced Colorectal Cancer","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2018-06-01","conditions":"Colorectal Cancer","enrollment":78},{"nctId":"NCT05447715","phase":"PHASE2","title":"Fruquintinib Sequential BEV+FOLFIRI vs. BEV+FOLFIRI Sequential Fruquintinib in Metastatic Colorectal Cancer","status":"UNKNOWN","sponsor":"Weijian Guo","startDate":"2022-08-31","conditions":"Metastatic Colorectal Cancer","enrollment":134},{"nctId":"NCT02330562","phase":"PHASE1, PHASE2","title":"Stage 1: Marizomib + Bevacizumab in WHO Gr IV GBM; Stage 2: Marizomib Alone; Stage 3: Combination of Marizomib and Bevacizumab","status":"COMPLETED","sponsor":"Celgene","startDate":"2015-04-15","conditions":"Malignant Glioma, Glioblastoma","enrollment":121},{"nctId":"NCT05353582","phase":"PHASE2","title":"Preoperative Systemic Therapy for Colorectal Cancer Peritoneal Metastases","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2022-06-01","conditions":"Colorectal Neoplasms, Colorectal Cancer, Colorectal Cancer Metastatic","enrollment":168},{"nctId":"NCT04389073","phase":"PHASE2","title":"Safety and Efficacy of Toripalimab in HER2- Metastatic Breast Cancer Patients Treated With Metronomic Vinorelbine","status":"UNKNOWN","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2020-04-01","conditions":"Metastatic Breast Cancer","enrollment":138},{"nctId":"NCT00464646","phase":"PHASE2","title":"Therapy With Bevacizumab (BEV), Epirubicin, and Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and BEV Given as Neoadjuvant or Adjuvant Therapy for Women With Locally Advanced HER2 Positive Invasive Breast Cancer","status":"COMPLETED","sponsor":"NSABP Foundation Inc","startDate":"2007-05","conditions":"Breast Cancer","enrollment":105},{"nctId":"NCT04781270","phase":"PHASE3","title":"mFOLFOXIRI+Bev vs. mFOLFOX6+Bev for RAS Mutant Unresectable Colorectal Liver-limited Metastases","status":"RECRUITING","sponsor":"Fudan University","startDate":"2021-04-15","conditions":"Colorectal Carcinoma, Liver Metastases","enrollment":308},{"nctId":"NCT04592029","phase":"PHASE1","title":"TACE Combined With Sintilimab and Bevacizumab for Unresectable HCC","status":"UNKNOWN","sponsor":"Second Affiliated Hospital of Guangzhou Medical University","startDate":"2020-09-27","conditions":"Hepatocellular Carcinoma Non-resectable","enrollment":36},{"nctId":"NCT00365417","phase":"PHASE2","title":"Therapy With Bevacizumab (BEV), Doxorubicin, and Cyclophosphamide Followed by BEV, Docetaxel, and Capecitabine Before Surgery Followed by BEV Alone After Surgery for Women With Locally Advanced Breast Cancer","status":"COMPLETED","sponsor":"NSABP Foundation Inc","startDate":"2006-08","conditions":"Breast Cancer","enrollment":45},{"nctId":"NCT04832776","phase":"PHASE2","title":"FOLFOXIRI Plus Cetuximab Versus FOLFOXIRI Plus Bevacizumab in Conversion Therapy of Right-sided Colon Cancer Liver Metastases","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2021-04-17","conditions":"Liver Metastasis Colon Cancer","enrollment":160},{"nctId":"NCT04508452","phase":"PHASE2","title":"A Phase II Prospective Trial of mXELOXIRI Reintroduction for mCRC","status":"UNKNOWN","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2020-05-18","conditions":"Unresectable Metastatic Colorectal Carcinoma","enrollment":91},{"nctId":"NCT01012297","phase":"PHASE3","title":"Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2009-11","conditions":"Recurrent Uterine Corpus Sarcoma, Stage IIIA Uterine Sarcoma, Stage IIIB Uterine Sarcoma","enrollment":107},{"nctId":"NCT00612586","phase":"PHASE2","title":"Study of Enzastaurin With 5-Fluorouracil/Leucovorin (5-FU/LV) Plus Bevacizumab as Maintenance Regimen Following First Line Therapy for Metastatic Colon Cancer","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2008-02","conditions":"Colorectal Cancer","enrollment":117},{"nctId":"NCT01803282","phase":"PHASE1","title":"Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2013-03-29","conditions":"Pancreatic Cancer, Non-small Cell Lung Cancer, Esophagogastric Cancer","enrollment":236},{"nctId":"NCT00602602","phase":"PHASE2","title":"Bevacizumab, Combination Chemotherapy, and Radiation Therapy in Treating Patients Undergoing Surgery For Locally Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2007-03","conditions":"Pancreatic Cancer","enrollment":19},{"nctId":"NCT01478321","phase":"PHASE2","title":"Efficacy of Hypofractionated XRT w/Bev. + Temozolomide for Recurrent Gliomas","status":"TERMINATED","sponsor":"Northwestern University","startDate":"2011-12-14","conditions":"Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Anaplastic Oligodendroglioma","enrollment":54},{"nctId":"NCT02339116","phase":"PHASE3","title":"Folfoxiri Plus Bev Followed by Reintroduction of Folfoxiri Plus Bev at Progression Versus Folfox Plus Bev Followed by Folfiri Plus Bev in mCRC","status":"UNKNOWN","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2015-02-26","conditions":"Metastatic Colorectal Cancer","enrollment":654},{"nctId":"NCT00600340","phase":"PHASE3","title":"2-arm Trial of Paclitaxel Plus Bevacizumab vs. Capecitabine Plus Bevacizumab","status":"COMPLETED","sponsor":"Central European Cooperative Oncology Group","startDate":"2008-04","conditions":"Metastatic Breast Cancer","enrollment":564},{"nctId":"NCT04160416","phase":"PHASE2","title":"mXELOXIRI Combined With Molecular Targeted Drug in mCRC","status":"UNKNOWN","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2019-07-01","conditions":"Unresectable Metastatic Colorectal Cancer","enrollment":48},{"nctId":"NCT03220932","phase":"PHASE3","title":"Cytoreductive Surgery and HIPEC in First or Secondary Platinum-resistant Recurrent Ovarian Epithelial Cancer","status":"UNKNOWN","sponsor":"Hospices Civils de Lyon","startDate":"2019-11-30","conditions":"Ovarian Epithelial Cancer","enrollment":132},{"nctId":"NCT04097444","phase":"PHASE2","title":"CAPOXIRI+Bevacizumab vs. FOLFOXIRI+Bevacizumab for mCRC","status":"UNKNOWN","sponsor":"Chugai Pharmaceutical","startDate":"2019-10-11","conditions":"Metastatic Colorectal Cancer","enrollment":112},{"nctId":"NCT02119026","phase":"PHASE2","title":"Efficacy And Safety Of Xeliri + Avastin Followed By Xelox + Avastin Or Reverse Sequence In Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Prof. Dr. Werner Scheithauer","startDate":"2011-02","conditions":"Metastatic Colorectal Cancer","enrollment":120},{"nctId":"NCT00252564","phase":"PHASE3","title":"Cetuximab, Bevacizumab & 5FU/Leucovorin vs. Oxaliplatin, Bevacizumab & 5FU/Leucovorin in Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"US Oncology Research","startDate":"2005-09","conditions":"Metastatic Colorectal Cancer","enrollment":247},{"nctId":"NCT03161041","phase":"PHASE2","title":"Perioperative Chemotherapy With Bevacizumab for Colorectal Carcinomatosis French Part of the Main Bev-IP Study","status":"WITHDRAWN","sponsor":"Hospices Civils de Lyon","startDate":"2018-09-21","conditions":"Colorectal Carcinomatosis","enrollment":""},{"nctId":"NCT01279681","phase":"PHASE3","title":"Combination Chemotherapy Plus Bevacizumab With or Without Oxaliplatin in Treating Older Patients With Metastatic Colorectal Cancer","status":"TERMINATED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2011-01","conditions":"Cognitive/Functional Effects, Colorectal Cancer, Neurotoxicity","enrollment":32},{"nctId":"NCT02623621","phase":"","title":"Soluble Vascular Endothelial Growth Factor Receptor 2 as Predictor of Benefit From Bevacizumab Beyond Progression in Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Azienda Ospedaliero, Universitaria Pisana","startDate":"2015-11","conditions":"Metastatic Colorectal Cancer","enrollment":103},{"nctId":"NCT00408408","phase":"PHASE3","title":"Chemotherapy With or Without Bevacizumab in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer That Can Be Removed By Surgery","status":"UNKNOWN","sponsor":"NSABP Foundation Inc","startDate":"2006-11","conditions":"Breast Cancer","enrollment":1206},{"nctId":"NCT00410605","phase":"PHASE2","title":"Bevacizumab, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Stage II or III Multiple Myeloma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2006-11","conditions":"Multiple Myeloma in Relapse, Stage II Multiple Myeloma, Stage III Multiple Myeloma","enrollment":39},{"nctId":"NCT00280150","phase":"PHASE1, PHASE2","title":"Combination Chemotherapy, Bev, RT, and Erlotinib in Treating Patients With Stage III Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2006-01","conditions":"Lung Cancer","enrollment":46},{"nctId":"NCT02023710","phase":"PHASE2","title":"Bevacizumab Combined With Carboplatin Plus Paclitaxel Chemotherapy to Treat Metastatic Mucosal Melanoma","status":"UNKNOWN","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2013-12","conditions":"Melanoma","enrollment":182}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":732,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["HLX04"],"phase":"marketed","status":"active","brandName":"Bevacizumab (Bev)","genericName":"Bevacizumab (Bev)","companyName":"Eli Lilly and Company","companyId":"eli-lilly","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Bevacizumab is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF), preventing tumor blood vessel formation and starving tumors of oxygen and nutrients. Used for Metastatic colorectal cancer (in combination with chemotherapy), Metastatic non-small cell lung cancer (in combination with chemotherapy), Metastatic breast cancer (in combination with chemotherapy).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}